Psychedelic and Dissociative Drugs as Medicines

This brief report highlights the current status of psychedelic and dissociative drugs in medicine, focusing on ketamine and esketamine. Ketamine, initially approved as an anesthetic, is now also used off-label for various mental health conditions, including depression, anxiety, and PTSD. Esketamine, a derivative of ketamine, received FDA approval in 2019 for treatment-resistant depression, administered under a Risk Evaluation and Mitigation Strategy (REMS) program due to potential risks. The report suggests that research is ongoing to explore the therapeutic potential of other psychedelic and dissociative substances. This research often involves controlled clinical trials investigating the efficacy and safety of these drugs in treating conditions like depression, anxiety, addiction, and trauma-related disorders. Substances under investigation include psilocybin, MDMA, and LSD. These trials are crucial for determining whether these drugs offer genuine therapeutic benefits and for establishing safe and effective treatment protocols. It's important to note that the report only mentions the existence of such research. The efficacy and safety profiles of these substances are still under investigation, and their use is not currently widespread or FDA-approved outside of specific research contexts. Future findings will determine the role of these substances in clinical practice.